PedAM
Pediatric Disease Annotations & Medicines
| Disease | open-angle glaucoma |
| Phenotype | C0028840|ocular hypertension |
| Sentences | 11 |
| PubMedID- 23035867 | The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis. |
| PubMedID- 19850843 | Methods: thirty subjects under treatment for open-angle glaucoma, 23 subjects with ocular hypertension, and 28 healthy subjects in a control group were investigated by monocular pattern electroretinogram (erg), l&m (long and medium wavelength) cone erg, and s (short wavelength)-cone erg. |
| PubMedID- 25863852 | Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. |
| PubMedID- 19432875 | Purpose: to estimate the effect of reducing intraocular pressure (iop) on: (i) the incidence of primary open-angle glaucoma (poag) in patients with ocular hypertension (oh), and (ii) the progression of glaucoma. |
| PubMedID- 22025865 | [2] additionally, a variety of medications and therapeutic options exist for both systemic hypertension and ocular hypertension associated with open-angle glaucoma. |
| PubMedID- 20181282 | Reducing iop prevents or delays the onset of open-angle glaucoma in patients with ocular hypertension [3] and slows progression among those with open-angle glaucoma [4-8]. |
| PubMedID- 23889862 | Slt is also safe as initial therapy in both open-angle glaucoma and patients with ocular hypertension [7,8]. |
| PubMedID- 21705084 | Purpose: to determine if the accuracy of the baseline prediction model for the development of primary open-angle glaucoma (poag) in patients with ocular hypertension can be improved by correcting intraocular pressure (iop) for central corneal thickness (cct). |
| PubMedID- 20582862 | This conference report highlights selected presentations on the development of fov-2304 (fovea pharmaceuticals sa) for the potential treatment of diabetic macular edema; pha-666859 (pfizer inc) for diabetic retinopathy; gtx-878 (gtx inc) and fcfd-4514s (genentech inc) for age-related macular degeneration; syl-040012 (sylentis sau) for ocular hypertension associated with open-angle glaucoma; peg-pla-tnp-470 (harvard medical school) for ocular neovascularization; recombinant galectin-3 (senju pharmaceutical co ltd) for corneal injury; and cellbead neuro (cellmed inc) for neurological trauma and neurodegeneration. |
| PubMedID- 25813999 | Purpose: the pathophysiology of ocular hypertension (oh) leading to primary open-angle glaucoma shares many features with a secondary form of oh caused by treatment with glucocorticoids, but also exhibits distinct differences. |
| PubMedID- 23316132 | Age was found to be predictive of open-angle glaucoma development in patients with ocular hypertension (gordon et al., 2002). |
Page: 1